Polysaccharide nanoparticles as potential immune adjuvants: Mechanism and function
Acta Pharmaceutica Sinica B · 2025-04 · 15 (4) · 1796-1815
DOI: 10.1016/j.apsb.2025.03.006 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Acta Pharmaceutica Sinica B, 2025-04. Verfasst von Yuhong Jiang und 2 weiteren Autor:innen. Beteiligte Einrichtung: Sichuan Engineering Research Center for Biomimetic Synthesis of Natural Drugs, School of Life Science and Engineering, Southwest Jiaotong University,…. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 144 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Sichuan Province Science and Technology Support Program, Chengdu Science and Technology Program, Fundamental Research Funds for the Central Universities.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Sichuan Engineering Research Center for Biomimetic Synthesis of Natural Drugs, School of Life Science and Engineering, Southwest Jiaotong University, Chengdu 610031, China.
Förderung
- Sichuan Province Science and Technology Support Program
- Chengdu Science and Technology Program
- Fundamental Research Funds for the Central Universities
- National Natural Science Foundation of China
Zitieren
APA
Jiang, Y., Qi, S., & Mao, C. (2025). Polysaccharide nanoparticles as potential immune adjuvants: Mechanism and function. Acta Pharmaceutica Sinica B, 15(4), 1796-1815. https://doi.org/10.1016/j.apsb.2025.03.006
Vancouver
Jiang Y, Qi S, Mao C. Polysaccharide nanoparticles as potential immune adjuvants: Mechanism and function. Acta Pharmaceutica Sinica B. 2025;15(4):1796-1815. doi:10.1016/j.apsb.2025.03.006
BibTeX
@article{Jiang2025,
author = {Jiang, Yuhong and Qi, Shanshan and Mao, Canquan},
title = {Polysaccharide nanoparticles as potential immune adjuvants: Mechanism and function},
journal = {Acta Pharmaceutica Sinica B},
year = {2025},
volume = {15},
number = {4},
pages = {1796--1815},
doi = {10.1016/j.apsb.2025.03.006}
}
EUVIMED